Stay updated on Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page
- Check4 days agoChange DetectedThe page’s displayed site revision/version number was updated from v3.5.2 to v3.5.3, reflecting a minor backend or UI release rather than a change to the trial record content.SummaryDifference0.0%

- Check11 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check40 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check48 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed.SummaryDifference0.0%

- Check76 days agoChange DetectedAdded Revision: v3.4.2 and removed the government funding lapse notice (Revision: v3.4.1) on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check83 days agoChange DetectedThe study record is updated to Completed with related identifiers and dates added. New data-sharing resources are linked (ProcedureAccessClinicalTrialData.pdf and external data sharing site), and the old Active, not recruiting status was removed.SummaryDifference0.9%

Stay in the know with updates to Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.